Asenapine vs Ziprasidone

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Asenapine

Marketed by AbbVie and partners

Approved in Schizophreniasmall molecule
Partial signal

NCT00212784 · Phase 3 · completed

This 52-week trial randomly assigned 1,225 people with schizophrenia to asenapine or to olanzapine, with participants, carers, investigators and outcome assessors all unaware of assignment. The primary measure was change in total PANSS symptom score. Asenapine improved symptoms by 21.0 points against 27.5 points for olanzapine, a difference favouring olanzapine at p<0.0001, so asenapine was less effective than its active comparator on this measure.

Reported efficacy

Change in total PANSS score at endpoint (Screening, Week 76, 100, and once every 24 weeks thereafter until endpoint): Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint (unclear)

Result source: NCT00212771

Ziprasidone

Marketed by Viatris and partners

Approved in Schizophreniasmall molecule
Partial signal

NCT00159770 · Phase 3 · completed

This 12-week, open-label, multicentre trial randomized 293 patients with chronic schizophrenia to ziprasidone (n=147) or to a comparator group of olanzapine, risperidone or quetiapine chosen by the investigator (n=146). The primary endpoint was total PANSS score, tested for non-inferiority with a margin of 7 points to the disadvantage of ziprasidone. Ziprasidone was non-inferior to the comparator group on total PANSS and on all subscores (P<0.0001), so the primary endpoint was met. The figures come from the peer-reviewed paper (Lublin et al., World J Biol Psychiatry 2009), whose abstract does not give a confidence interval.

Next expected readout: February 2027 · NCT03781115 (registry estimate)

Reported efficacy

Number of Events Recorded Based on Ziprasidone Side Effects Checklist During Randomized Trial (From Baseline up to Week 8); Change From Baseline in Simpson Angus Scale for Extrapyramidal Symptoms (SAS) (Baseline, Week 2, Week 4, Week 6, Week 8); Change From Baseline in the Barnes Akathisia Scale (BAS) (Baseline, Week 2, Week 4, Week 6, Week 8); Number of Participants With High and Low Levels in Serum Prolactin Concentration (Baseline, Week 8); Vital Signs: Systolic and Diastolic Blood Pressure Levels (Baseline, Week 1, Week 2, Week 4, Week 6, Week 8); Electrocardiogram (EKG): Number of Participants With an Increase From Baseline to Corrected QT (QTc) Interval >/= 500 Milliseconds (Msec) (6 hours after dosing of Weeks 1, 2 and 8); Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline, Week 2, Week 4, Week 6, Week 8); Percentage of Participants With Response (Baseline, Week 2, Week 4, Week 6, Week 8); Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Score (Baseline, Week 2, Week 4, Week 6, Week 8); Number of Treatment-emergent Adverse Events During Randomized Trial (From Baseline up to Week 8): Change from baseline in PANSS total score at Week 8, high-dose ziprasidone (320 mg/day) vs standard dose (160 mg/day plus placebo capsules): -8.62 vs -5.48, mixed-model difference -1.37 (95% CI -7.20 to 4.45), p=0.642. No registered primary favoured the high dose; the Simpson-Angus extrapyramidal score was worse on the high dose at Week 2 (difference 1.02, 95% CI 0.08 to 1.95, p=0.033). (missed)

Result source: NCT00403546

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAsenapineZiprasidone
PANSS total, change-25.5 vs -17.8−7.7 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
18 other results
  • -21.7 vs -16.2 5 mg BID · wk 6 · n 111 · Phase 3 · primary NCT01617187
  • -12.2 vs -0.9 5 mg BID · wk 6 · n 173 · Phase 3 · primary NCT01098110
  • -14.2 vs -0.9 10 mg BID · wk 6 · n 178 · Phase 3 · primary NCT01098110
  • -23.7 vs -17.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · primary NCT01190254
  • -17.4 vs -16.2 2.5 mg BID · wk 6 · n 96 · Phase 3 · primary NCT01617187
  • -19 vs -15.4 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -17.1 vs -15.5 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -14.8 vs -13.2 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -12.5 vs -10.7 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -9.1 vs -7.1 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -4.9 vs -4.8 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -17 vs -15.4 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -12.3 vs -15.5 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -12 vs -13.2 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -9.9 vs -10.7 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -7.2 vs -7.1 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -4 vs -4.8 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
  • -21 vs -27.5 wk 52 · Phase 3 · primary NCT00212784
—Not posted · NCT00159770
CGI-S, change-1.3 vs -0.8−0.5 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
17 other results
  • -1.2 vs -1 5 mg BID · wk 6 · n 111 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.2 5 mg BID · wk 6 · n 173 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.7 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -0.2 vs -0.2 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.2 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · secondary NCT01190254
  • -0.9 vs -1 2.5 mg BID · wk 6 · n 96 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.8 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.7 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -0.1 vs -0.2 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
-1.2 vs -1.2vs Haloperidolwk 0.43 · n 188NCT00723606
PANSS response39.3% vs 20.7%+18.6 vs placebo5 mg BID · wk 6 · n 173NCT01098110
1 other result
  • 43.8% vs 20.7% 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
—Not posted · NCT00159770
PSP, change—Not posted · NCT00212771—Not posted · NCT00159770
Relapse (% of patients)—Not posted · NCT00212771—Not posted · NCT00159770

PANSS total, change

Asenapine
-25.5 vs -17.8−7.7 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
18 other results
  • -21.7 vs -16.2 5 mg BID · wk 6 · n 111 · Phase 3 · primary NCT01617187
  • -12.2 vs -0.9 5 mg BID · wk 6 · n 173 · Phase 3 · primary NCT01098110
  • -14.2 vs -0.9 10 mg BID · wk 6 · n 178 · Phase 3 · primary NCT01098110
  • -23.7 vs -17.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · primary NCT01190254
  • -17.4 vs -16.2 2.5 mg BID · wk 6 · n 96 · Phase 3 · primary NCT01617187
  • -19 vs -15.4 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -17.1 vs -15.5 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -14.8 vs -13.2 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -12.5 vs -10.7 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -9.1 vs -7.1 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -4.9 vs -4.8 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -17 vs -15.4 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -12.3 vs -15.5 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -12 vs -13.2 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -9.9 vs -10.7 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -7.2 vs -7.1 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -4 vs -4.8 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
  • -21 vs -27.5 wk 52 · Phase 3 · primary NCT00212784
Ziprasidone
—Not posted · NCT00159770

CGI-S, change

Asenapine
-1.3 vs -0.8−0.5 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
17 other results
  • -1.2 vs -1 5 mg BID · wk 6 · n 111 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.2 5 mg BID · wk 6 · n 173 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.7 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -0.2 vs -0.2 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.2 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · secondary NCT01190254
  • -0.9 vs -1 2.5 mg BID · wk 6 · n 96 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.8 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.7 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -0.1 vs -0.2 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
Ziprasidone
-1.2 vs -1.2vs Haloperidolwk 0.43 · n 188NCT00723606

PANSS response

Asenapine
39.3% vs 20.7%+18.6 vs placebo5 mg BID · wk 6 · n 173NCT01098110
1 other result
  • 43.8% vs 20.7% 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
Ziprasidone
—Not posted · NCT00159770

PSP, change

Asenapine
—Not posted · NCT00212771
Ziprasidone
—Not posted · NCT00159770

Relapse (% of patients)

Asenapine
—Not posted · NCT00212771
Ziprasidone
—Not posted · NCT00159770
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety

Coverage. Asenapine: 8 of 8 rows · Ziprasidone: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAsenapine
Rows use multiple source trials
Ziprasidone
Rows use multiple source trials
CGI-I
absolute value · score
2.5 vs 3.1 placebo score @ 8wk5.0 mg BIDa,b,c,d
NCT01190254 · Phase 3 · registry result, not featured evidence
show 1 more dose
2.8 vs 3.1 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
2.52 vs 2.55 Haloperidol score @ 0.43wkb,c,d
NCT00723606 · Phase 3 · registry result, not featured evidence
HbA1c
absolute change · percentage points
No placebo or comparator arm
0% (n=79) @ 52wke,b,c,f
NCT01244828 · Phase 3 · registry result, not featured evidence
0.1% (n=127) @ 16wke,b,c,f
NCT00406315 · Phase 4 · registry result, not featured evidence
PANSS Total
absolute change · score
No placebo or comparator arm
-11.08 score @ 52wka,b,c
NCT01244828 · Phase 3 · registry result, not featured evidence
show 1 more dose
-5.48 score
NCT01244828 · Phase 3 · registry result, not featured evidence
-8.62 score @ 8wkHigh doseb,c
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
Weight
absolute change · kg
No placebo or comparator arm
0.25 kg @ 52wke,b,c,f
NCT01244828 · Phase 3 · registry result, not featured evidence
-1.09 kg @ 16wke,b,c,f
NCT00406315 · Phase 4 · registry result, not featured evidence
Dropout rate
44.4%5 mg twice dailyg
NCT01549041 · Phase 4 · registry result, not featured evidence
show 23 more results
16.7%10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
54.8%5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence
0%5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
1%2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
49.7%
NCT01244828 · Phase 3 · registry result, not featured evidence
35.2%5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
40.1%10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
50%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
20.9%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
20.8%5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
17.3%2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
33.7%
NCT00174265 · Phase 3 · registry result, not featured evidence
50.4%
NCT00145496 · Phase 3 · registry result, not featured evidence
30.4%
NCT00150176 · Phase 3 · registry result, not featured evidence
15.7%
NCT00265343 · Phase 3 · registry result, not featured evidence
67.7%
NCT00156065 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
33.3%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
25%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—High doseh
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
show 9 more results
—High dose
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
26.8%
NCT00338949 · Phase 4 · registry result, not featured evidence
58.5%
NCT00406315 · Phase 4 · registry result, not featured evidence
12.5%
NCT00351000 · Phase 4 · registry result, not featured evidence
2.1%
NCT00723606 · Phase 3 · registry result, not featured evidence
99.1%
NCT00139737 · Phase 3 · registry result, not featured evidence
88.4%
NCT00174447 · Phase 3 · registry result, not featured evidence
35.7%
NCT00538642 · Phase na · registry result, not featured evidence
0%
NCT00225498 · Phase na · registry result, not featured evidence
Discontinued due to AEs
22.2%5 mg twice dailyg
NCT01549041 · Phase 4 · registry result, not featured evidence
show 23 more results
0%10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
22.3%5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence
0%5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
0%2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
23.6%
NCT01244828 · Phase 3 · registry result, not featured evidence
17%5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
17.6%10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
0%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
5.1%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
7.5%5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
6.1%2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
8.1%
NCT00174265 · Phase 3 · registry result, not featured evidence
17.2%
NCT00145496 · Phase 3 · registry result, not featured evidence
8.2%
NCT00150176 · Phase 3 · registry result, not featured evidence
7.5%
NCT00265343 · Phase 3 · registry result, not featured evidence
11.8%
NCT00156065 · Phase 3 · registry result, not featured evidence
—5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—High doseh
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
show 9 more results
—High dose
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
—
NCT00338949 · Phase 4 · registry result, not featured evidence
16.2%
NCT00406315 · Phase 4 · registry result, not featured evidence
—
NCT00351000 · Phase 4 · registry result, not featured evidence
1.1%
NCT00723606 · Phase 3 · registry result, not featured evidence
16.9%
NCT00139737 · Phase 3 · registry result, not featured evidence
44.2%
NCT00174447 · Phase 3 · registry result, not featured evidence
—
NCT00538642 · Phase na · registry result, not featured evidence
—
NCT00225498 · Phase na · registry result, not featured evidence
Serious AEs
0%5 mg twice dailyg
NCT01549041 · Phase 4 · registry result, not featured evidence
show 23 more results
0%10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
20.4%5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence
4.4%5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
5.2%2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
8.9%
NCT01244828 · Phase 3 · registry result, not featured evidence
5.7%5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
2.8%10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
12.5%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
3.6%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
2.8%5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
3.1%2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
4.7%
NCT00174265 · Phase 3 · registry result, not featured evidence
12.3%
NCT00145496 · Phase 3 · registry result, not featured evidence
3.1%
NCT00150176 · Phase 3 · registry result, not featured evidence
6.7%
NCT00265343 · Phase 3 · registry result, not featured evidence
14.1%
NCT00156065 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—High doseh
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
show 9 more results
10.5%High dose
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
6.7%
NCT00338949 · Phase 4 · registry result, not featured evidence
9.1%
NCT00406315 · Phase 4 · registry result, not featured evidence
0%
NCT00351000 · Phase 4 · registry result, not featured evidence
0%
NCT00723606 · Phase 3 · registry result, not featured evidence
9.7%
NCT00139737 · Phase 3 · registry result, not featured evidence
30.2%
NCT00174447 · Phase 3 · registry result, not featured evidence
0%
NCT00538642 · Phase na · registry result, not featured evidence
0%
NCT00225498 · Phase na · registry result, not featured evidence
Most frequent reported AEs
5 mg twice dailyg
daytime drowsiness 22.2%
NCT01549041 · Phase 4 · registry result, not featured evidence
show 19 more results
10 mg daily in the evening
daytime drowsiness 0%
NCT01549041 · Phase 4 · registry result, not featured evidence
5/10 mg BID
nasopharyngitis 21.7%
schizophrenia 10.8%
somnolence 10.8%
NCT01142596 · Phase 3 · registry result, not featured evidence
5 mg BID
insomnia 15% (placebo 13.9%)
headache 8.8% (placebo 2%)
anxiety 7.1% (placebo 11.9%)
NCT01617187 · Phase 3 · registry result, not featured evidence
2.5 mg BID
headache 10.3% (placebo 2%)
insomnia 9.3% (placebo 13.9%)
anxiety 7.2% (placebo 11.9%)
NCT01617187 · Phase 3 · registry result, not featured evidence
nasopharyngitis 21%
somnolence 12.7%
weight increased 12.7%
NCT01244828 · Phase 3 · registry result, not featured evidence
5 mg BID
akathisia 11.4% (placebo 5.2%)
hypoaesthesia oral 10.9% (placebo 3.4%)
insomnia 9.7% (placebo 12.1%)
NCT01098110 · Phase 3 · registry result, not featured evidence
10 mg BID
schizophrenia 13.8% (placebo 24.1%)
somnolence 12.2% (placebo 1.7%)
akathisia 10.5% (placebo 5.2%)
NCT01098110 · Phase 3 · registry result, not featured evidence
accidental overdose 12.5%
acne 12.5%
akathisia 12.5%
NCT01190267 · Phase 3 · registry result, not featured evidence
somnolence 14.8%
headache 6.6%
sedation 5.1%
NCT01190267 · Phase 3 · registry result, not featured evidence
5.0 mg BID
somnolence 17% (placebo 6.9%)
sedation 11.3% (placebo 2%)
insomnia 9.4% (placebo 5.9%)
NCT01190254 · Phase 3 · registry result, not featured evidence
2.5 mg BID
somnolence 20.4% (placebo 6.9%)
dizziness 7.1% (placebo 1%)
headache 7.1% (placebo 5.9%)
NCT01190254 · Phase 3 · registry result, not featured evidence
insomnia 10.6%
weight increased 5.9%
headache 2.4%
NCT00174265 · Phase 3 · registry result, not featured evidence
insomnia 17.6%
somnolence 14.8%
headache 13.5%
NCT00145496 · Phase 3 · registry result, not featured evidence
insomnia 20.1% (placebo 24.5%)
somnolence 16% (placebo 17.2%)
weight increased 14.4% (placebo 10.9%)
NCT00150176 · Phase 3 · registry result, not featured evidence
headache 5.2%
influenza 5.2%
schizophrenia 5.2%
NCT00265343 · Phase 3 · registry result, not featured evidence
insomnia 18.5%
headache 10.9%
parkinsonism 10.9%
NCT00156065 · Phase 3 · registry result, not featured evidence
5 mg
dystonia 66.7%
dizziness 33.3%
nausea 33.3%
NCT01206517 · Phase 1 · registry result, not featured evidence
10 mg
hypoaesthesia oral 50%
dizziness 38.9%
dysgeusia 38.9%
NCT01206517 · Phase 1 · registry result, not featured evidence
2.5 mg
sedation 33.3%
dysgeusia 16.7%
hypoaesthesia oral 16.7%
NCT01206517 · Phase 1 · registry result, not featured evidence
High doseh
hypertension 18.4%
somnolence 15.8%
headache 10.5%
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
show 6 more results
insomnia 6.7%
akathisia 3.3%
NCT00338949 · Phase 4 · registry result, not featured evidence
insomnia 19.1%
somnolence 14.5%
nausea 11.6%
NCT00406315 · Phase 4 · registry result, not featured evidence
difficulty breathing 4.2%
dizziness 4.2%
NCT00351000 · Phase 4 · registry result, not featured evidence
dizziness 3.7%
somnolence 3.7%
akathisia 3.2%
NCT00723606 · Phase 3 · registry result, not featured evidence
electrocardiogram qt prolonged 13.9%
insomnia 6.3%
anxiety 4.5%
NCT00139737 · Phase 3 · registry result, not featured evidence
anxiety 23.3%
insomnia 16.3%
schizophrenia 14%
NCT00174447 · Phase 3 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 0.43 weeks versus 8 weeks.
  5. eTrial phases differ: Phase 4 versus Phase 3.
  6. fAssessment timepoints differ: 16 weeks versus 52 weeks.
  7. gPopulation comparability has not been reviewed for these studies.
  8. hPopulation comparability has not been reviewed for 8 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Asenapine

BPRS Total 7.72 score @ 2wk5 mg twice daily
absolute change · score
No placebo or comparator arm
NCT01549041 · Phase 4 · registry result, not featured evidence
show 1 more result
16.08 score @ 2wk10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
Time to Loss of Efficacy 5.82 months5/10 mg BID
time to event · months
Extension (open-label)
No placebo or comparator arm
NCT01142596 · Phase 3 · registry result, not featured evidence · converted to months from 177 days as posted
show 1 more result
12.09 months*5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence · converted to months from 368 days as posted
PANSS Total -21.7 vs -16.2 placebo score @ 6wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 18 more results
-4.9 vs -4.8 placebo score @ 0.57wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-9.1 vs -7.1 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-12.5 vs -10.7 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-14.8 vs -13.2 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-17.1 vs -15.5 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-19 vs -15.4 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-12.24 vs -0.95 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-25.5 vs -17.8 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-14.17 vs -0.95 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-17.4 vs -16.2 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4 vs -4.8 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.2 vs -7.1 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-9.9 vs -10.7 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-12 vs -13.2 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-12.3 vs -15.5 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-17 vs -15.4 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-23.7 vs -17.8 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-21 vs -27.5 olanzapine score @ 52wk
NCT00212784 · Phase 3 · sponsor-reported, not registry data
PANSS 30% 25.2% (n=111) vs 19.2% (n=99) placebo @ 6wk5 mg BID
responder rate · % of participants
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
0% (n=111) vs 2.1% (n=99) placebo @ 0.57wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
5.4% (n=111) vs 5.1% (n=99) placebo @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
5.4% (n=111) vs 7.1% (n=99) placebo @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
14.4% (n=111) vs 13.1% (n=99) placebo @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
16.2% (n=111) vs 14.1% (n=99) placebo @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
21.6% (n=111) vs 17.2% (n=99) placebo @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
49% (n=104) vs 36% (n=100) placebo @ 8wk*5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence · converted to % from 51 participants as posted
72.1% (n=104) vs 62% (n=100) placebo @ 8.4wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
14.6% (n=96) vs 19.2% (n=99) placebo @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
0% (n=96) vs 2.1% (n=99) placebo @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
2.1% (n=96) vs 5.1% (n=99) placebo @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
5.2% (n=96) vs 7.1% (n=99) placebo @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
8.3% (n=96) vs 13.1% (n=99) placebo @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
10.4% (n=96) vs 14.1% (n=99) placebo @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
15.6% (n=96) vs 17.2% (n=99) placebo @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
50% (n=96) vs 36% (n=100) placebo @ 8wk*2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence · converted to % from 48 participants as posted
64.2% (n=96) vs 62% (n=100) placebo @ 8.4wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
Weight 1.3 vs 0.3 placebo kg @ 6wk5 mg BID
absolute change · kg
NCT01617187 · Phase 3 · registry result, not featured evidence
show 2 more results
1.3 vs 0.3 placebo kg @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
0 vs 2.6 Olanzapine kg @ 26wk
NCT00145496 · Phase 3 · registry result, not featured evidence
CGI-I 33.3% (n=111) vs 37.8% (n=99) placebo @ 0.57wk5 mg BID
responder rate · % of participants
NCT01617187 · Phase 3 · registry result, not featured evidence
show 19 more results
46.8% (n=111) vs 45.5% (n=99) placebo @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
60.4% (n=111) vs 54.5% (n=99) placebo @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
63.1% (n=111) vs 58.6% (n=99) placebo @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
62.2% (n=111) vs 60.6% (n=99) placebo @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
64% (n=111) vs 64.6% (n=99) placebo @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
66.7% (n=111) vs 62.6% (n=99) placebo @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
63.6% (n=173) vs 41.4% (n=174) placebo @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
39.4% (n=104) vs 28% (n=100) placebo @ 8wk*5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence · converted to % from 41 participants as posted
60.1% (n=104) vs 54.7% (n=100) placebo @ 8.3wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
70.2% (n=178) vs 41.4% (n=174) placebo @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
34.7% (n=96) vs 37.8% (n=99) placebo @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
51% (n=96) vs 45.5% (n=99) placebo @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
51% (n=96) vs 54.5% (n=99) placebo @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
54.2% (n=96) vs 58.6% (n=99) placebo @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
58.3% (n=96) vs 60.6% (n=99) placebo @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
60.4% (n=96) vs 64.6% (n=99) placebo @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
59.4% (n=96) vs 62.6% (n=99) placebo @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
37.5% (n=96) vs 28% (n=100) placebo @ 8wk*2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence · converted to % from 36 participants as posted
47.1% (n=96) vs 54.7% (n=100) placebo @ 8.3wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Negative -0.5 vs -0.8 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 15 more results
-1.3 vs -1.1 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -1.8 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.3 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.1 vs -3 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.4 vs -2.6 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.3 vs -3.2 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.72 vs -0.24 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-3.27 vs -0.24 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-0.7 vs -0.8 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.2 vs -1.1 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.6 vs -1.8 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -2.3 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -3 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.3 vs -2.6 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.3 vs -3.2 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
PANSS Positive -1.6 vs -1.7 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 15 more results
-2.8 vs -2.6 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.9 vs -3.7 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5 vs -4.5 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.7 vs -5 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.3 vs -5.5 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.2 vs -5.4 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.31 vs -0.85 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-4.63 vs -0.85 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-1.2 vs -1.7 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -2.6 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.4 vs -3.7 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4 vs -4.5 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.1 vs -5 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.2 vs -5.5 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.6 vs -5.4 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
PANSS General Psychopathology -2.7 vs -2.4 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-4.9 vs -3.6 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.2 vs -5.4 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.4 vs -6.7 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-8.2 vs -7.7 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-9.2 vs -7.6 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-10.1 vs -8 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.26 vs 0.19 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-11.5 vs -8.5 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-6.34 vs 0.19 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-2.2 vs -2.4 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.8 vs -3.6 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.1 vs -5.4 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.9 vs -6.7 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.9 vs -7.7 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-8.8 vs -7.6 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-8.9 vs -8 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-10.9 vs -8.5 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Marder Positive -1.8 vs -2 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-2.9 vs -2.8 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4 vs -4.1 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.4 vs -5.1 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.3 vs -5.6 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.7 vs -6.1 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.6 vs -6.2 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.78 vs -1.37 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-8.9 vs -6.1 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-5.03 vs -1.37 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-1.3 vs -2 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.8 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.9 vs -4.1 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.5 vs -5.1 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.8 vs -5.6 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.1 vs -6.1 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.8 vs -6.2 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.9 vs -6.1 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Marder Negative -0.8 vs -0.7 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-1.9 vs -1.3 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.8 vs -2 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.2 vs -2.5 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.8 vs -3.5 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.9 vs -3 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.7 vs -4 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.77 vs -0.41 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-5.3 vs -3.7 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-3.35 vs -0.41 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-1.2 vs -0.7 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.7 vs -1.3 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2 vs -2 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.6 vs -2.5 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.9 vs -3.5 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.5 vs -3 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.4 vs -4 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.2 vs -3.7 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Marder Disorganized Thought -0.7 vs -0.7 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-1.4 vs -0.7 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2 vs -1.5 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.1 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.1 vs -2.4 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.5 vs -2.4 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.3 vs -2.7 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.48 vs 0.24 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-4.8 vs -3.4 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-2.85 vs 0.24 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-0.3 vs -0.7 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1 vs -0.7 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.3 vs -1.5 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -2.1 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.4 vs -2.4 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.5 vs -2.4 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.8 vs -2.7 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.3 vs -3.4 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence

+ 29 further endpoints in the CSV export.

Ziprasidone

PANSS 24.2% (n=33) @ 2wkHigh dose
responder rate · % of participants
No placebo or comparator arm
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
show 3 more results
23.1% (n=33) @ 4wkHigh dose
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
36.4% (n=33) @ 6wkHigh dose
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
33.3% (n=33) @ 8wkHigh dose
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
CGI-S -0.25 score @ 8wkHigh dose
absolute change · score
No placebo or comparator arm
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
show 1 more result
-0.76 score @ 16wk
NCT00406315 · Phase 4 · registry result, not featured evidence
CGI-I -0.57 score @ 8wkHigh dose
absolute value · score
No placebo or comparator arm
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
show 1 more result
2.7 score @ 16wk
NCT00406315 · Phase 4 · registry result, not featured evidence
Insulin Sensitivity 0.407 vs 0.072 Control minutes @ 26wk
absolute change · minutes
NCT00338949 · Phase 4 · registry result, not featured evidence
Visceral Adipose Tissue Volume 392 vs 315 Control mm @ 26wk
absolute change · mm
NCT00338949 · Phase 4 · registry result, not featured evidence
Total Cholesterol Change mg/dL -3 mg @ 16wk
absolute change · mg
No placebo or comparator arm
NCT00406315 · Phase 4 · registry result, not featured evidence
Fasting Glucose Change mg/dL 0.17 mmol/L @ 16wk
absolute change · mmol/L
No placebo or comparator arm
NCT00406315 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 3 mg/dL as posted
show 2 more results
0.28 mmol/L @ 6wk*
NCT00351000 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from 5 mg/dL as posted
-0.25 mmol/L @ 6wk*
NCT00351000 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -4.5 mg/dL as posted
Fasting Insulin 134.8 mL @ 16wk
absolute change · mL
No placebo or comparator arm
NCT00406315 · Phase 4 · registry result, not featured evidence
PANSS Total -6.61 score @ 16wk
absolute change · score
No placebo or comparator arm
Total Score, Week 16 LOCF (n=231)
NCT00406315 · Phase 4 · registry result, not featured evidence
PANSS Positive Subscale -2.43 score @ 16wk
absolute change · score
No placebo or comparator arm
Positive Subscale Score, Week 16 LOCF (n=231)
NCT00406315 · Phase 4 · registry result, not featured evidence
PANSS Negative Subscale -0.92 score @ 16wk
absolute change · score
No placebo or comparator arm
Negative Subscale Score, Week 16 LOCF (n=231)
NCT00406315 · Phase 4 · registry result, not featured evidence
CDSS -2.55 score @ 16wk
absolute change · score
No placebo or comparator arm
NCT00406315 · Phase 4 · registry result, not featured evidence

+ 16 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asenapine's landscape · Ziprasidone's landscape